Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 16 of 16 for “"exendin-4"”.
-
Exendin 4 Conjugation and Sequence Modification to Treat Type 2 Diabetes and Obesity
… <p>(PK) of the diabetes drug exendin 4 (Ex-4), and vitamin B12 (B12) bioconjugates, thereof.</p> <p>Q1. (Chapter 2) What effect does B12 conjugation to Ex-4 have on agonism of the glucagon-like peptide-1</p> <p>receptor (GLP-1R) in vitro and on PD/PK (including brain uptake and …
-
The binding and activation of the glucagon-like peptide-1 receptor by exendin-4
Background and purpose Exendin-4 (EX4) has the same physiological properties as glucagon-like peptide-1 (7-36)amide (GLP-1). EX4 has 50% identity with GLP-1, with an extra nine amino acids at its C-terminus. The two peptides mediate their functions through coupling to the glucagon like peptide-1 …
-
The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on cell viability, ADAM10 maturation and the proteolysis of ADAM10 substrates in SH-SY5Y cells
… Dulaglutide, Liraglutide, and Exenatide (Exendin-4), currently used to treat diabetes, may also be beneficial in the treatment of neurodegenerative conditions such as AD, as they have been shown to exert neuroprotective properties. Research has also suggested that one of these compounds, …
-
Perinatal hypoxic-ischemic brain injury – characterization, mechanisms and treatment
… to find suitable additive treatments, such as Exendin-4. I showed that global cerebral ischemia was associated with a striking increase in concentration of adenosine triphosphate in the cerebrospinal fluid at 6 hours in near-term fetal sheep. Curiously, the increase in adenosine triphosphate …
-
Gut-brain axis: Central impact of gut peptides and metabolic drug on monoamine neurotransmission
… glucagon-like-peptide-1 (GLP-1) receptor agonist exendin-4 as well as putative GLP-1 congener geniposide, can affect the electrical activity of dopamine neurons in the ventral tegmental area (VTA) and of pyramidal neurons in the prefrontal cortex (PFC), using single-unit activity recording …
-
Vitamin B12 Bioconjugates In Pharmaceutical Design
… observations.</p> <p>Q4: (Chapter 4) Does B12-Exendin-4, a conjugate of B12 and the diabetes drug exendin-4 (Ex-4; a peptide agonist of the glucagon like peptide receptor 1) show reduced central nervous system (CNS) penetrance, thus reducing the common side effect of nausea that is observed in …
-
Phasic Dopamine Signaling During Ingestion: Modulation Across the Need-to-Satiety Arc
… modulated dopamine responses to sucrose. Exendin-4, but not Semaglutide, significantly suppressed dopamine release without influencing slope of decline, indicating a reduction in overall dopamine activity. This difference may be due to pharmacokinetics properties, as Exendin-4 crosses the …
-
Targeting macrophages GLP-1 receptor pathways as emerging therapies to ameliorate cardiac remodelling associated with diabetes
… have recently reported that the GLP-1 analogue, exendin-4, promotes specific benefits on cardiac inflammation and ECM remodelling in a mouse model of experimental diabetes. Besides its direct action to maintain cardiovascular function and indirect action to control cardiovascular risk factors, it …
-
Novel Roles of GLP-1 and GLP-2 in the Regulation of Hepatic Lipid/Lipoprotein Homeostasis and the Involvement of BAT Activation
… showed that the GLP-1 receptor (GLP-1R) agonist exendin-4 decreased body weight, fasting dyslipidemia and VLDL overproduction by enhancing lipid utilization and decreasing hepatic de novo lipogenesis. These effects occurred through a vagal signalling pathway and were independent of changes in …
-
An investigation into the aggregation of therapeutic peptides through adsorption to primary containers
… in this thesis; glucagon, liraglutide, g797 and exendin-4 are all used or on trial for mediating blood glucose levels as a safe and effective treatment for type 2 diabetes. One of the largest drawbacks of peptides is their ability to aggregate and adsorb to surfaces that they come into contact …
-
Extrapancreatic actions of incretin-based therapies on bone in diabetes mellitus
… independent of metabolic status. Twice-daily Exendin-4 therapy improved glycaemic control and increased work required to resist bone fracture in high-fat fed mice. It was also established that Sitagliptin had neutral effects on bone microstructure and mechanical strength in high-fat mice. In …
-
Encapsulation as a 3D model for human embryonic stem cell propagation and differentiation
… were made by supplementing the GLP-1R agonist, exendin-4 (Ex-4) to the culture media during each stage of differentiation. However, Ex-4 supplementation had no additive effect on cell viability. In contrast, further investigation demonstrated a significant reduction of the DE gene expression …
-
Investigation of insulinotropic and cytoprotective effects of selected amphibian skin peptides
… gained momentum, following the development of exendin-4 in the early 2000 derived from the saliva of the Gila monster (Heloderma suspectum), into a clinically available anti-diabetic drug. Previous studies have demonstrated the anti-diabetic effects of amphibian peptides such as tigerinin-1R, …
-
Exploring the function and sensing mechanisms of human enteroendocrine cells using intestinal organoids
… stimuli, including tryptophan, GLP1R agonist exendin-4 and bile acid sensing receptor GPBAR agonist GPBAR-A, induce 5-HT release in vitro. Building upon previous work from our laboratory, which delved into the secretory properties of human GLP-1-secreting L-cells and motilin-producing M-cells, …